Related Experiment Videos
Rotavirus vaccine AVANT/GlaxoSmithKline
1Intellivax International Inc, Ville St-Laurent, Quebec, Canada. tjones@intellivax.com
Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
Summary
A two-dose oral rotavirus vaccine shows promise in preventing rotavirus gastroenteritis (RGE) in young children for at least two years. Further development and phase III studies are planned.
Area of Science:
- Vaccinology
- Pediatric Infectious Diseases
- Gastroenterology
Background:
- Rotavirus gastroenteritis (RGE) is a significant cause of illness in young children globally.
- Development of effective rotavirus vaccines is crucial for public health.
- AVANT Immunotherapeutics and GlaxoSmithKline are collaborating on a novel live oral rotavirus vaccine.
Purpose of the Study:
- To evaluate the efficacy and safety of a two-dose oral rotavirus vaccine.
- To assess the duration of protective immune response against prevalent rotavirus strains.
- To support further clinical development, including phase III trials.
Main Methods:
- Phase II clinical efficacy trial of a live oral rotavirus vaccine.
- Second-year surveillance extension study to assess long-term protection.
- Initiation of phase I/II bridging studies in Europe.
Main Results:
- The two-dose oral rotavirus vaccine demonstrated potential in preventing RGE in young children.
- Protection was observed for at least two years following administration.
- Phase III safety and efficacy studies were planned for 2001.
Conclusions:
- The rotavirus vaccine candidate RIX-4414 shows sustained efficacy in preventing rotavirus gastroenteritis.
- The vaccine has the potential for broad protection against common rotavirus strains.
- Further clinical trials are warranted to confirm safety and efficacy in larger populations.